HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N Guiso Selected Research

Whooping Cough (Pertussis)

10/2020Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis, France, 2013.
11/2014Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
5/2014Antibody-mediated inhibition of Bordetella pertussis adenylate cyclase-haemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population.
1/2013Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome.
9/2012Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
3/2011What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.
2/2011Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009.
1/2011[Bordetella bronchiseptica-associated acute chest syndrome in a child with sickle cell disease].
7/2010Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy.
10/2009First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


N Guiso Research Topics

Disease

24Whooping Cough (Pertussis)
10/2020 - 04/2000
7Infections
11/2014 - 04/2000
2Bordetella Infections
10/2005 - 08/2000
1Vaccine-Preventable Diseases
05/2014
1Zoonoses
01/2011

Drug/Important Bio-Agent (IBA)

15VaccinesIBA
10/2020 - 07/2000
4Pertussis ToxinIBA
02/2011 - 02/2007
3Pertussis VaccineIBA
10/2020 - 12/2001
3Virulence Factors (Pathogenicity Factors)IBA
11/2014 - 11/2001
3pertactinFDA Link
11/2014 - 08/2000
3AntigensIBA
05/2014 - 02/2009
3Biological ProductsIBA
01/2013 - 10/2003
2Immunoglobulin G (IgG)IBA
03/2011 - 02/2011
2Adenylate Cyclase ToxinIBA
04/2000 - 04/2000
1Acellular VaccinesIBA
10/2020
1AntibodiesIBA
05/2014
1mutalipocin IIIBA
03/2011
1Complement System Proteins (Complement)IBA
03/2011
1Immunoglobulin A (IgA)IBA
03/2011
1EnzymesIBA
02/2011
1ImmunosorbentsIBA
02/2011
1Indicators and Reagents (Reagents)IBA
02/2009
1Nucleic AcidsIBA
10/2005
1MacrolidesIBA
08/2005
1Adenylyl Cyclases (Adenylyl Cyclase)IBA
11/2001
1Immune Sera (Antisera)IBA
04/2001
1Membrane Proteins (Integral Membrane Proteins)IBA
08/2000
1Hemagglutinins (Hemagglutinin)IBA
04/2000
1Proteins (Proteins, Gene)FDA Link
04/2000
1Bacterial ToxinsIBA
04/2000
1Superoxides (Superoxide)IBA
04/2000
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2000

Therapy/Procedure

1Medical Day Care (Partial Hospitalization)
08/2005
1Antibiotic Prophylaxis
08/2005